1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1586/ern.09.51" target="_blank" rel="noreferrer noopener">http://doi.org/10.1586/ern.09.51</a>
Pages
1073–1085
Issue
7
Volume
9
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
Publisher
An entity responsible for making the resource available
Expert review of neurotherapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-07
Subject
The topic of the resource
Humans; Animals; Structure-Activity Relationship; Serotonin/*metabolism; Drug Design; Alzheimer Disease/*complications; Cognition Disorders/*drug therapy/*etiology; Serotonin Antagonists/chemistry/*therapeutic use; Receptors; Biological; Models
Creator
An entity primarily responsible for making the resource
Geldenhuys Werner J; Van der Schyf Cornelis J
Description
An account of the resource
The serotonin 6 receptor is attracting attention as an etiological contributor in cognition deficits in diseases such as Alzheimer's disease, anxiety/depression and schizophrenia. In this review, we discuss the role of this recently discovered G protein-coupled receptor in cognition and memory, particularly in Alzheimer's disease. A surge in publications that describe the development of ligands for this receptor have recently come to light, underscoring the emerging interest in this receptor as a drug target. We also explore the current status of structure-activity relationship studies that have focused on the design of novel antagonists for the serotonin 6 receptor.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1586/ern.09.51" target="_blank" rel="noreferrer noopener">10.1586/ern.09.51</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2009
Alzheimer Disease/*complications
Animals
Biological
Cognition Disorders/*drug therapy/*etiology
Drug Design
Expert review of neurotherapeutics
Geldenhuys Werner J
Humans
Models
Receptors
Serotonin Antagonists/chemistry/*therapeutic use
Serotonin/*metabolism
Structure-Activity Relationship
Van der Schyf Cornelis J
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1586/14737175.2015.990884" target="_blank" rel="noreferrer noopener">http://doi.org/10.1586/14737175.2015.990884</a>
Pages
3–5
Issue
1
Volume
15
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacotherapy of Alzheimer's disease: current and future trends.
Publisher
An entity responsible for making the resource available
Expert review of neurotherapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-01
Subject
The topic of the resource
Humans; Alzheimer's disease; Alzheimer Disease/*drug therapy; anti-inflammatory agents; antioxidants; cholinesterase inhibitors; dementia; Drug Therapy/*methods/*trends; immunotherapy; memantine; multi-targeted drugs; natural products; pharmacotherapy
Creator
An entity primarily responsible for making the resource
Geldenhuys Werner J; Darvesh Altaf S
Description
An account of the resource
Alzheimer's disease (AD) and its related dementia has shown an alarming rise in the global population. Although considerable efforts have been made to develop effective therapeutic agents for AD therapy, drug development has not met significant clinical success. Current pharmacotherapy of AD is limited to cholinesterase inhibitors and the N-methyl-D-aspartate antagonist memantine. Considerable research is underway to develop newer agents for the management of AD. Since amyloid-beta (Abeta) has been implicated in AD pathogenesis, the use of beta secretase inhibitors as well as immunotherapy against Abeta has been investigated. A considerable effort has been spent investigating the therapeutic potential of antioxidants and anti-inflammatory agents, several of natural products and dietary origin, in AD treatment. Numerous drug targets have also been investigated for AD treatment and a modest drug pipeline is available. Despite these efforts, drug development for AD has proved extremely difficult and most clinical trials have afforded disappointing results.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1586/14737175.2015.990884" target="_blank" rel="noreferrer noopener">10.1586/14737175.2015.990884</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
Alzheimer Disease/*drug therapy
Alzheimer's disease
Anti-Inflammatory Agents
Antioxidants
cholinesterase inhibitors
Darvesh Altaf S
dementia
Department of Pharmaceutical Sciences
Drug Therapy/*methods/*trends
Expert review of neurotherapeutics
Geldenhuys Werner J
Humans
immunotherapy
memantine
multi-targeted drugs
natural products
NEOMED College of Pharmacy
Pharmacotherapy
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1586/ern.10.42" target="_blank" rel="noreferrer noopener">http://doi.org/10.1586/ern.10.42</a>
Pages
729–745
Issue
5
Volume
10
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents.
Publisher
An entity responsible for making the resource available
Expert review of neurotherapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-05
Subject
The topic of the resource
Humans; Animals; Oxidative Stress/drug effects/*physiology; Alzheimer Disease/*physiopathology/*therapy; Antioxidants/*administration & dosage/chemistry/pharmacology; Flavonoids/*administration & dosage/chemistry/pharmacology; Mitochondria/drug effects/physiology; Neurodegenerative Diseases/physiopathology; Phenols/*administration & dosage/chemistry/pharmacology; Polyphenols
Creator
An entity primarily responsible for making the resource
Darvesh Altaf S; Carroll Richard T; Bishayee Anupam; Geldenhuys Werner J; Van der Schyf Cornelis J
Description
An account of the resource
Oxidative stress has been strongly implicated in the pathophysiology of neurodegenerative disorders such as Alzheimer's disease (AD). In recent years, antioxidants - especially those of dietary origin - have been suggested as possible agents useful for the prevention and treatment of AD. This article reviews the role of oxidative stress and the contribution of free radicals in the development of AD, and also discusses the use of antioxidants as a therapeutic strategy in the amelioration of this illness. The antioxidant potential of polyphenolic compounds obtained from dietary sources, such as anthocyanins from berries, catechins and theaflavins from tea, curcumin from turmeric, resveratrol from grapes and peanuts, the dihydrochalcones aspalathin and nothofagin from rooibos and the xanthone mangiferin from honeybush, are discussed in this review. The neuroprotective effects of these phytochemicals in preclinical models of AD are highlighted. Finally, innovative concepts, novel hypotheses, current challenges and future directions in the use of dietary polyphenols for the treatment of AD are discussed.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1586/ern.10.42" target="_blank" rel="noreferrer noopener">10.1586/ern.10.42</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Alzheimer Disease/*physiopathology/*therapy
Animals
Antioxidants/*administration & dosage/chemistry/pharmacology
Bishayee Anupam
Carroll Richard T
Darvesh Altaf S
Department of Pharmaceutical Sciences
Expert review of neurotherapeutics
Flavonoids/*administration & dosage/chemistry/pharmacology
Geldenhuys Werner J
Humans
Mitochondria/drug effects/physiology
NEOMED College of Pharmacy
Neurodegenerative Diseases/physiopathology
Oxidative Stress/drug effects/*physiology
Phenols/*administration & dosage/chemistry/pharmacology
Polyphenols
Van der Schyf Cornelis J